Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Summary not available.
Summary not available.
AptarGroup, Inc. (NYSE: ATR) has been recognized as the top company on Forbes' inaugural Green Growth 50 list for 2021. This accolade highlights Aptar's commitment to reducing greenhouse gas emissions while achieving earnings growth. Aptar aims to have over 60% of its facilities certified as Landfill Free by year-end and emphasizes the importance of sustainable solutions in its business strategies. The company focuses on recyclability, renewable energy, and sustainable product design in collaboration with organizations like the Ellen MacArthur Foundation.
Summary not available.
AptarGroup, Inc. (NYSE:ATR) reported a 9% increase in Q3 2021 sales, reaching $825 million, mainly from strong performance in Beauty + Home and Food + Beverage. Adjusted earnings per share (EPS) were $0.94, down from $1.01 a year ago, due to restructuring and investment losses. The Pharma segment experienced slight sales declines, impacted by lower demand in prescription markets. The company completed acquisitions enhancing its capabilities in medical and digital solutions. Looking ahead, EPS is projected between $0.88 and $0.96 for Q4, with focus on cost containment amid rising inflation.
AptarGroup, Inc. (NYSE:ATR) announced that its patented Cartridge Pump System (CPS) has been reviewed by the U.S. FDA for use in Oyster Point Pharma's TYRVAYA™ Nasal Spray, the first FDA-approved nasal treatment for dry eye disease. This approval marks a significant milestone, confirming Aptar's expertise in drug delivery solutions. The CPS is designed for multidose delivery of both preserved and non-preserved formulations, aiding in the treatment of symptoms associated with dry eye disease, impacting approximately 38 million adults in the U.S.
AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, with a payment date set for November 17, 2021. Shareholders of record as of October 27, 2021, are eligible for this dividend. The company will also host a conference call on October 29, 2021, at 8:00 a.m. CT to discuss its third quarter results. Aptar, headquartered in Crystal Lake, Illinois, specializes in drug delivery and consumer product dispensing solutions.
AptarGroup, Inc. (NYSE: ATR) will host a virtual Capital Markets Day on September 10, 2021, starting at 9:00 a.m. EDT. Senior executives will present and participate in a Q&A session. Interested parties can access the event via the Investor Relations page. A replay will be available for 30 days post-event. Aptar is a leader in drug delivery and consumer product dispensing, operating in various markets such as pharmaceutical and beauty, with a workforce of 13,000 across 20 countries.
AptarGroup, Inc. (NYSE: ATR) announced the passing of Dr. Joanne Smith, a long-time member of its Board of Directors, who served since 1999. Dr. Smith was also the Chairwoman of the Corporate Governance Committee and was revered for her deep market insights and leadership style. Her contributions significantly impacted Aptar's success over the past 22 years, as noted by Chairman George Fotiades and President & CEO Stephan B. Tanda. The company appreciates her guidance and expresses deep gratitude for her commitment.
AptarGroup, Inc. (NYSE: ATR) has successfully acquired a majority stake of approximately 64.6% in Voluntis for €8.70 per share. Following this acquisition, Aptar will initiate a mandatory cash tender offer for the remaining shares at the same price. The transaction has received approval from the French Ministry of Economy and is expected to enhance Aptar's position in drug delivery solutions.
The company's board will issue an opinion on the tender offer, guided by an independent expert report. The current management of Voluntis is expected to remain post-acquisition.